Leukemia Research
Volume 36, Issue 3 , Pages 271-274 , March 2012

Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model

  • Beate Schultheis

      Affiliations

    • Department of Haematology, Imperial College and Hammersmith Hospital, London, UK
    • Corresponding Author InformationCorresponding author. Present address: Department of Haematology and Medical Oncology, University of Bochum, Marienhospital Herne, Hoelkeskampring 40, 44625 Herne, Germany. Tel.: +49 2323 499 1641; fax: +49 2323 499 362.
    • ,
  • Bart A. Nijmeijer

      Affiliations

    • Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • H. Yin

      Affiliations

    • Center for Reproductive Medicine and Infertility, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Roger G. Gosden

      Affiliations

    • Center for Reproductive Medicine and Infertility, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Junia V. Melo

      Affiliations

    • Department of Haematology, Imperial College and Hammersmith Hospital, London, UK
    • Present address: Department of Haematology, Centre for Cancer Biology, SA Pathology and University of Adelaide, Adelaide, SA, Australia.

Received 17 March 2011 ,Revised 11 September 2011 ,Accepted 22 September 2011.

References 

  1. Hochhaus A, O‘Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054–1061
  2. Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw. 2009;7:1050–1058
  3. Ault P, Kantarjian H, O‘Brien S, Faderl S, Beran M, Rios MB, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24:1204–1208
  4. Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med. 2008;358:1079–1080
  5. Brougham MF, Wallace WH. Subfertility in children and young people treated for solid and haematological malignancies. Br J Haematol. 2005;131:143–155
  6. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30:126–132
  7. Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J. 2007;37:190–192
  8. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40:21–25
  9. Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med. 2004;351:2134–2135
  10. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein–tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139–145
  11. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein–tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–104
  12. Yoon SJ, Kim KH, Chung HM, Choi DH, Lee WS, Cha KY, et al. Gene expression profiling of early follicular development in primordial, primary, and secondary follicles. Fertil Steril. 2006;85:193–203
  13. Carlsson IB, Laitinen MP, Scott JE, Louhio H, Velentzis L, Tuuri T, et al. Kit ligand and c-Kit are expressed during early human ovarian follicular development and their interaction is required for the survival of follicles in long-term culture. Reproduction. 2006;131:641–649
  14. Sleer LS, Taylor CC. Cell-type localization of platelet-derived growth factors and receptors in the postnatal rat ovary and follicle. Biol Reprod. 2007;76:379–390
  15. Hutt KJ, McLaughlin EA, Holland MK. KIT/KIT ligand in mammalian oogenesis and folliculogenesis: roles in rabbit and murine ovarian follicle activation and oocyte growth. Biol Reprod. 2006;75:421–433
  16. Nilsson EE, Detzel C, Skinner MK. Platelet-derived growth factor modulates the primordial to primary follicle transition. Reproduction. 2006;131:1007–1015
  17. Domingues TS, Rocha AM, Serafini PC. Tests for ovarian reserve: reliability and utility. Curr Opin Obstet Gynecol. 2010;22:271–276
  18. Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 2005;24:6432–6440
  19. Faddy MJ, Telfer E, Gosden RG. The kinetics of pre-antral follicle development in ovaries of CBA/Ca mice during the first 14 weeks of life. Cell Tissue Kinet. 1987;20:551–560
  20. Gosden RG, Laing SC, Felicio LS, Nelson JF, Finch CE. Imminent oocyte exhaustion and reduced follicular recruitment mark the transition to acyclicity in aging C57BL/6J mice. Biol Reprod. 1983;28:255–260
  21. Schlatt S, Kim SS, Gosden R. Spermatogenesis and steroidogenesis in mouse, hamster and monkey testicular tissue after cryopreservation and heterotopic grafting to castrated hosts. Reproduction. 2002;124:339–346
  22. Qian H, Xu J, Lalioti MD, Gulle K, Sakkas D. Oocyte numbers in the mouse increase after treatment with 5-aminoisoquinolinone: a potent inhibitor of poly(ADP-ribosyl)ation. Biol Reprod. 2010;82:1000–1007
  23. Heartin E, Walkinshaw S, Clark RE. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma. 2004;45:1307–1308
  24. Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505–5508
  25. Kierszenbaum AL. Tyrosine protein kinases and spermatogenesis: truncation matters. Mol Reprod Dev. 2006;73:399–403
  26. Hutt KJ, McLaughlin EA, Holland MK. Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod. 2006;12:61–69
  27. Mariani S, Basciani S, Arizzi M, Spera G, Gnessi L. PDGF and the testis. Trends Endocrinol Metab. 2002;13:11–17
  28. Gonfloni S, Di TL, Caldarola S, Cannata SM, Klinger FG, Di BC, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009;15:1179–1185
  29. Conchon M, Sanabani SS, Bendit I, Santos FM, Serpa M, Dorliac-Llacer PE. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol. 2009;2:42
  30. Oweini H, Otrock ZK, Mahfouz RA, Bazarbachi A. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet. 2011;283:133–134
  31. Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, Dorliac-Llacer PE, Bendit I. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010, Article ID 136252.
  32. Kroll T, Ames MB, Pruett JA, Fenske TS. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma. 2010;51:1751–1753
  33. O‘Brien S, Berman E, Borghaei H, DeAngelo DJ, Devetten MP, Devine S, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009;7:984–1023

PII: S0145-2126(11)00468-1

doi: 10.1016/j.leukres.2011.09.025

Leukemia Research
Volume 36, Issue 3 , Pages 271-274 , March 2012

Article Tools

* Image Usage & Resolution